Telomir Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 14, 2025
TELO$0.71-9.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Financial Statements (unaudited)Condensed Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024
CONDENSED BALANCE SHEETS
| June 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash | $754,323 | $1,266,131 |
| Prepaid expenses | 75,288 | 57,874 |
| Total current assets | 829,611 | 1,324,005 |
| Total assets | $829,611 | $1,324,005 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Trade accounts payable and accrued liabilities | $254,956 | $587,536 |
| Due to related parties | 93,432 | 93,432 |
| Total current liabilities | 348,388 | 680,968 |
| Total liabilities | $348,388 | $680,968 |
| Stockholders’ Equity | ||
| Preferred Stock, no par value, 100,000,000 shares authorized and none issued or outstanding. | - | - |
| Common Stock, no par value; 300,000,000 shares authorized, 30,514,304 and 29,762,671 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively. | - | - |
| Additional paid-in capital | 38,327,799 | 31,239,895 |
| Accumulated deficit | (37,846,576) | (30,596,858) |
| Total stockholders’ equity | 481,223 | 643,037 |
| Total liabilities and stockholders’ equity | $829,611 | $1,324,005 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.